Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies

Cancer Cell(2020)10.1016/j.ccell.2020.05.004Source: DataRank Database

Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies is a research paper published in Cancer Cell (2020). On theSindex it has a DataRank of 0. It has been cited 159 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access159 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 7.14)OA: bronzeTopics (57)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

Amanda N. Henning ORCID,Tori N. Yamamoto ORCID,Zhiya Yu ORCID,Nikolaos Zacharakis ORCID,Sri Krishna ORCID

Live enrichment

PubMed:32516591 PMC:PMC10323690 OpenAlex:https://openalex.org/W3033006672

Intramural NIH HHS

Grant: Z01 BC010763

Intramural NIH HHS

Grant: ZIA BC011855

National Institutes of Health

Milken Family Foundation

National Cancer Institute

FWCI

7.14

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.cell.com/article/S1535610820302543/pdf

publisherhttp://www.cell.com/article/S1535610820302543/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1535610820302543?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610820302543?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ccell.2020.05.004

Fields of Study

CAR-T cell therapy researchCRISPR and Genetic EngineeringT-cell and B-cell ImmunologyAnimalsBreast NeoplasmsCRISPR-Cas SystemsCell DifferentiationFemaleGenetic EngineeringImmunotherapy, AdoptiveMaleMelanoma, ExperimentalMiceMice, Inbred C57BLMice, KnockoutPhenotypeReceptors, Antigen, T-CellT-Lymphocytesp38 Mitogen-Activated Protein Kinases

MeSH Terms

AnimalsBreast NeoplasmsCell DifferentiationFemaleGenetic EngineeringMaleMelanoma, ExperimentalMice, Inbred C57BLPhenotypeReceptors, Antigen, T-CellT-LymphocytesImmunotherapy, AdoptiveMice, Knockoutp38 Mitogen-Activated Protein KinasesMiceCRISPR-Cas Systems

Keywords

CRISPRPhenotypeBiologyCancer cellKinaseCas9Cancer researchCell biologyRegulatorGeneCancerGeneticsDNA damageDifferentiationROSP38NY-ESO-1Adoptive Transfer ImmunotherapyCrispr-cas9 ScreenNeoantigen TilCd19 Car T CellMulti-phenotype

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Strategies to enhance CAR-T persistence

10.6084/m9.figshare.21622536.v1figshare

Additional file 1 of Strategies to enhance CAR-T persistence

10.6084/m9.figshare.21622536figshare